Industry
Biotechnology
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Vandana Singh
August 14, 2024 | 4:06 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 11:18 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 8:04 pm
Portfolio Pulse from Benzinga Newsdesk
July 22, 2024 | 6:21 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 11:56 am
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 8:40 pm
Portfolio Pulse from Benzinga Newsdesk
March 15, 2024 | 10:43 am
Portfolio Pulse from Happy Mohamed
March 14, 2024 | 8:04 pm
Portfolio Pulse from Benzinga Newsdesk
February 27, 2024 | 8:13 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.